Assessment of DNA Damage in Leukocytes of Patients With Coronary Artery Disease by Comet Assay

作者：Bhat Mohd Akbar^*; Gandhi Gursatej

来源：International Heart Journal, 2017, 58(2): 271-274.

DOI：10.1536/ihj.16-190

• Genetic damage
• SCGE assay
• CAD subtypes
• Peripheral blood leukocytes
• Drug therapy

DNA damage in the peripheral blood leukocytes (PBL) of patients with coronary artery disease (CAD) was investigated using the sensitive alkaline single cell gel electrophoresis (SCGE)/comet assay.
This case-control study consisted of CAD patients (n = 200; mean age, 59.04 +/- 0.75 years) undergoing treatment at local hospitals and age-, sex-, and ethnicity-matched healthy controls (n = 200; mean age, 57.88 +/- 0.96 years) from the general population.
CAD patients had significantly (P < 0.001) increased DNA damage (tail DNA percent (T-DNA %) 22.45 +/- 0.50 versus 5.81 +/- 0.28; tail moment (TM) 89.35 +/- 3.16 versus 9.98 +/- 0.69; Olive tail moment (OTM) 60.50 +/- 1.79 versus 10.94 +/- 0.63; damage frequency (DF) 91.12 +/- 0.93 versus 41.78 +/- 2.04, damage index (DI) 173.68 +/- 3.36 versus 48.53 +/- 2.59) compared to controls. Patients with acute myocardial infarction (AMI) showed significantly higher DNA damage than patients with unstable angina (UA) (T-DNA % 24.05 +/- 0.87 versus 21.06 +/- 0.90; TM 100.02 +/- 6.19 versus 81.61 +/- 5.84; OTM 66.19 +/- 3.20 versus 56.47 +/- 3.33; DF 94.02 +/- 0.84 versus 91.10 +/- 1.16, DI 184.13 +/- 5.33 versus 166.42 +/- 5.89). Moreover, DNA damage was found to be significantly (P < 0.05) elevated in patients receiving ecosprin, ramipril, and metoprolol therapy compared to aspirin and nitrocontin.
The increased DNA damage in CAD patients may be the consequence of disease and/or drug therapy. These observations are of concern because unrepaired DNA can lead to malignancy, and the likelihood of increasing mortality and morbidity rates in CAD patients.

• 出版日期2017-3